Genitourinary cancers, spanning a wide range of malignancies affecting both the urinary and reproductive systems, represent a significant global health challenge. These malignancies affect millions of individuals worldwide and are associated with substantial morbidity and mortality. Recent advancements in understanding the molecular and genetic underpinnings of these cancers have paved the way for innovative diagnostic and therapeutic approaches. As researchers continue to explore the complexities of genitourinary tumors, a clearer picture of their pathophysiology is emerging, which is crucial for developing targeted treatment strategies.

The ongoing research in genitourinary cancers is pivotal for improving patient outcomes. With the advent of precision medicine, immunotherapy, and novel biomarker identification, there have been significant strides in tailoring treatments to individual patients. For instance, the incorporation of genomic profiling in clinical practice has revolutionized our approach to managing prostate cancer, enabling more effective and personalized therapies. Furthermore, ongoing clinical trials are continually expanding our knowledge base, ultimately aiming to enhance survival rates and quality of life for patients diagnosed with these cancers.

Continued research in this field holds the promise of further breakthroughs in diagnostics and treatment modalities. As our understanding of the molecular drivers of genitourinary cancers deepens, we may witness the development of innovative therapeutic agents, enhanced screening methods, and more effective strategies for early detection. Future research could also lead to better integration of multidisciplinary approaches, offering hope for improved management and outcomes for patients facing these challenging diseases.

This Collection welcomes research articles on topics including, but not limited to:

- Genetic mutations and molecular pathways in genitourinary cancers

- Advances in biomarker discovery for early detection

- Imaging technology for early detection

- Liquid biopsy

-Genomic testing for personalized treatment plans

- Immuno-oncology combinations and novel drug classes

- Role of surgery and minimally invasive procedures

- Targeted therapies for specific genitourinary malignancies

- Overcoming resistance to chemotherapy and targeted therapies

- New clinical trials and cutting-edge research

- Translational research bridging laboratory findings to clinical applications

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

In recent past, minimally invasive surgery has become standard for treating various types of cancers because of the way it is designed to reduce the physical trauma associated with traditional open surgeries, particularly in procedures like prostatectomy, colectomies, and hysterectomies. By utilizing smaller incisions and advanced imaging technologies such as high-definition cameras and 3D visualization, MIS has improved surgical outcomes and precision, allowing for faster recovery times, reduced blood loss, and shorter hospital stays.

For example, robotic-assisted techniques used in prostate cancer surgery or gynecologic oncological procedures enable precise dissection and tumor removal while preserving surrounding tissue and organs, reducing the risk of nerve damage or organ injury. Similarly, in colorectal cancer surgery, robotic-assisted laparoscopic techniques allow surgeons to perform complex resections with greater accuracy, minimizing the risk of bowel obstruction and anastomotic leaks, while preserving critical vascular structures and improving the overall recovery process. Recent innovations have led to more refined surgical techniques, improved robotic instrumentation, and better training for surgical teams, resulting in reduced rates of postoperative pain, fewer infections, and quicker rehabilitation times.

However, MIS also faces challenges. Knowing when it is the best treatment option is key to achieving optimal outcomes. In some cases, the limitations of MIS, such as difficulty visualizing deeper or hidden tumors, may impact outcomes.

With this in mind, BMC Cancer is opening this Collection on "Minimally invasive cancer surgery." We welcome submissions on the following:

Advances in robotic-assisted surgical techniques

Patient outcomes in minimally invasive cancer surgery

Comparative effectiveness of traditional vs. minimally invasive approaches

Innovations in surgical instrumentation and technology

Identification of optimal scenarios for minimally invasive surgery, considering factors like cancer type, stage, and patient health